BioCardia (BCDA) vs Pluri (PLUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioCardia (BCDA) has outperformed Pluri (PLUR) over the past year, losing 25.4% versus a loss of 75.5%. Over five years, PLUR leads with a -95.2% price change compared with -97.6% for BCDA. BioCardia is the larger company by market cap ($16.0 million vs $12.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCDA | PLUR |
|---|---|---|
| Share price | $1.06 | $1.00 |
| Market cap | $16.05M | $12.61M |
| 1-day change | -2.75% | -3.85% |
| YTD return | -15.20% | -66.56% |
| 1-year return | -25.35% | -75.49% |
| 5-year return | -97.59% | -95.23% |
| EPS (TTM) | $-0.63 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.80 | $4.87 |
| 52-week low | $0.75 | $0.85 |
| Distance from 52-week high | -41.11% | -79.47% |
| Analyst consensus | none | — |
| Avg. price target upside | +1362.26% | — |
| Average volume | 282.05K | 24.97K |
| Shares outstanding | 15.14M | 12.61M |
| Employees | 17 | 92 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCDA has outperformed PLUR by 50.1 percentage points over the past year.
About BioCardia
BCDA stock →BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Healthcare · Biotechnology · 17 employees
About Pluri
PLUR stock →Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform.
Healthcare · Biotechnology · 92 employees
BCDA vs PLUR FAQ
Which is bigger, BioCardia or Pluri?
BioCardia (BCDA) is larger, with a market capitalization of $16.05M compared with $12.61M for Pluri (PLUR).
Which stock has performed better over the past year, BCDA or PLUR?
BCDA returned -25.35% over the past 12 months, compared with -75.49% for PLUR (price return, excluding dividends). Past performance does not predict future results.
Are BioCardia and Pluri in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.